KRAS and melanoma: Casula et al. [31] observed CDKN2A mutation in 11 of 16 metastatic tumors but not in paired primary melanomas whereas Goswami et al. [32] observed heterogeneity in KRAS and KIT mutations between paired cases of primary and metastatic melanomas.